ReviewCNS drugs2015
Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease.
Review in CNS drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Long-Term Quality of Life Trend after Subthalamic Stimulation for Parkinson's Disease: An Updated Systematic Review and Meta-Analysis.Movement disorders clinical practice · 2025Pooled it
- Pooled it
- Efficacy of pramipexole on quality of life in patients with Parkinson's disease: a systematic review and meta-analysis.BMC neurology · 2022Pooled it
- Trial
- Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.Journal of Parkinson's disease · 2020Trial
- Efficacy of intensive multidisciplinary rehabilitation in Parkinson's disease: a randomised controlled study.Journal of neurology, neurosurgery, and psychiatry · 2018Trial
- Effects of deep brain stimulation on functional autonomy and quality of life in Parkinson's disease: A systematic review and meta-analysis.Journal of Parkinson's disease · 2026Review
- Factors associated with self-rated health in people with late-stage parkinson's and cognitive impairment.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Health-Related Quality of Life in Patients with Inherited Ataxia in Ireland.Cerebellum (London, England) · 2024Article
- Article
- Possible Implications of Managing Alexithymia on Quality of Life in Parkinson's Disease: A Systematic Review.Parkinson's disease · 2024Review
- Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease.Neurology · 2022Article
- Management of systemic risk factors ahead of dental implant therapy: A beard well lathered is half shaved.Journal of leukocyte biology · 2021Review
- Impact of a Collaborative Pharmaceutical Care Service for Patients With Parkinson's Disease.Frontiers in pharmacology · 2021Article
- An artificial neural network approach to detect presence and severity of Parkinson's disease via gait parameters.PloS one · 2021Article
- Gender Differences and Quality of Life in Parkinson's Disease.International journal of environmental research and public health · 2020Review
- Interpretation of health-related quality of life outcomes in Parkinson's disease from the EARLYSTIM Study.PloS one · 2020Article
- [Remote assessment of idiopathic Parkinson's disease : Developments in diagnostics, monitoring and treatment].Der Nervenarzt · 2019Review
- The Evolution of Quality of Life After Subthalamic Stimulation for Parkinson's Disease: A Meta-Analysis.Movement disorders clinical practice · 2019Review
- Effects of blackberry (Journal of experimental pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quality of life (QoL) is a patient-reported outcome frequently included in Parkinson's disease (PD) clinical trials as a secondary or tertiary endpoint. However, QoL is an important variable that reflects the impact of disease and treatment from the patients' perspective. In a chronic, neurodegenerative disease such as PD, with a wide range of complex symptoms, QoL provides valuable and comprehensive information on the patients' health status. This narrative review aims to evaluate the effect of specific PD treatments currently in use on patients' QoL measured with the Parkinson's Disease Questionnaire, 39-item (PDQ-39) or 8-item (PDQ-8) version. A quantification of this effect is provided by calculation of the relative change and effect size. These two parameters allow an intuitive standardized approach to the importance of change based on its magnitude. Some high-quality studies (Level I) were found for levodopa (immediate- or extended-release formulations), levodopa with added-on catechol-O-methyltransferase (COMT) inhibitors, levodopa/carbidopa gel for intestinal infusion, some dopamine agonists (ropinirole, cabergoline, pergolide), and the monoamine oxidase B (MAO-B) inhibitor safinamide. As a whole, these studies found a beneficial effect of variable magnitude, weak to moderate, on patients' QoL. Studies with a lower level of evidence or not providing enough data to estimate relative change and effect size, including those for the apomorphine subcutaneous pump, also reported improvement of QoL, but the evidence was insufficient to confirm the effect. More high-quality studies focused on QoL are needed to determine the real impact of PD drug treatments for this important outcome.
Indexed as
Identifiers
25968563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.